Screening for cervical cancer in primary care a decision analysis for the us preventive services task force

JAMA - Journal of the American Medical Association

Volumn 320, Issue 7, 2018, Pages 706-714

  Kim, Jane J ^b   Burger, Emily A ^a,b   Regan, Catherine ^b   Sy, Stephen ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; FALSE POSITIVE RESULT; FEMALE; HUMAN; INCIDENCE; MORTALITY RATE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCREENING TEST; UTERINE CERVIX CANCER; ADVISORY COMMITTEE; AGED; DECISION SUPPORT SYSTEM; EARLY CANCER DIAGNOSIS; HEALTH CARE QUALITY; ISOLATION AND PURIFICATION; LIFE EXPECTANCY; MASS SCREENING; MIDDLE AGED; MORTALITY; PAPILLOMAVIRIDAE; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; UNITED STATES; UTERINE CERVIX; UTERINE CERVIX TUMOR; UTILIZATION; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADULT; ADVISORY COMMITTEES; AGED; CERVIX UTERI; COLPOSCOPY; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; LIFE EXPECTANCY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PRACTICE GUIDELINES AS TOPIC; PROCESS ASSESSMENT (HEALTH CARE); UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 85051965117     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.19872     Document Type: Article

References (27)

1. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2013;158(11):852]. Ann Intern Med. 2012;156(12): 880-891.
2. Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172.
3. Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol. 2012;120(5):1222-1238.
4. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178-182.
5. Melnikow J, Henderson JT, Burda BU, et al. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the U.S. Preventive Services Task Force: Evidence Synthesis No. 158. Rockville, MD: Agency for Healthcare Research and Quality; 2017. AHRQ publication 17-05231-EF-1.
6. Campos NG, Burger EA, Sy S, et al. An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol. 2014;180(5): 545-555.
7. Kim JJ, Campos NG, Sy S, et al; New Mexico HPV Pap Registry Steering Committee. Inefficiencies and high-value improvements in U.S. cervical cancer screening practice: a cost-effectiveness analysis. Ann Intern Med. 2015;163(8):589-597.
8. National Center for Health Statistics (NCHS). 2010 National Hospital Discharge Survey (NHDS) public use micro-data file and documentation. NCHS website. https://www.cdc.gov/nchs/nhds/nhds_questionnaires.htm. 2012. Accessed January 31, 2017.
9. University of California Berkeley. Berkeley Mortality Database. http://www.demog.berkeley.edu/~bmd. Accessed August 2, 2016.
10. National Cancer Institute. Surveillance, Epidemiology, End Results (SEER) Cancer Statistics Review, 1975-2013. https://seer.cancer.gov/archive/csr/1975_2013/. September 12, 2016. Accessed January 31, 2017.
11. Wheeler CM, Hunt WC, Cuzick J, et al; New Mexico HPV Pap Registry Steering Committee. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2013;132(1):198-207.
12. Joste NE, Ronnett BM, Hunt WC, et al; New Mexico HPV Pap Registry Steering Committee. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):230-240.
13. Saraiya M, Unger ER, Thompson TD, et al; HPV Typing of Cancers Workgroup. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015; 107(6):djv086.
14. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104(1):232-246.
15. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J; Athena HPV Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):184.e1-184.e11.
16. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(suppl 5):F88-F99.
17. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7(7):547-555.
18. Ronco G, Segnan N, Giorgi-Rossi P, et al; New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst. 2006;98(11):765-774.
19. Cuzick J, Myers O, Hunt WC, et al; New Mexico HPV Pap Registry Steering Committee. A population-based evaluation of cervical screening in the United States: 2008-2011. Cancer Epidemiol Biomarkers Prev. 2014;23(5):765-773.
20. Cuzick J, Myers O, Hunt WC, et al; New Mexico HPV Pap Registry Steering Committee. Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management. Int J Cancer. 2015;136(12):2854-2863.
21. Kinney W, Hunt WC, Dinkelspiel H, Robertson M, Cuzick J, Wheeler CM; New Mexico HPV Pap Registry Steering Committee. Cervical excisional treatment of young women: a population-based study. Gynecol Oncol. 2014;132(3):628-635.
22. Ogilvie GS, Krajden M, van Niekerk D, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017;140(2):440-448.
23. Massad LS, Einstein MH, Huh WK, et al; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S1-S27.
24. Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. J Low Genit Tract Dis. 2013;17(2):193-202.
25. Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123(6):1044-1050.
26. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014; 120(13):2032-2038.
27. Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288.